Low resistance of Li-intercalated unfavourable electrodes is essential for the secure and quick charging required for large-scale batteries. Right here, we demonstrated that nanosized two-dimensional crystalline fragrant dicarboxylate unfavourable electrode supplies synthesized through spray drying exhibit low inside resistances at roughly 0.7 V vs Li/Li+, whereas retaining flat potential profiles. The spray-dried pattern with a hole construction is crushed into nanoflakes throughout ink preparation for electrode coating and kinds a uniform and extremely dispersed electrode construction.
The charge-discharge analysis signifies that the nanoflake pattern confirmed smaller charge-discharge polarization than the majority pattern with secure biking traits, leading to vital high-rate property enhancement. Cost-transfer resistance of the nanoflake pattern reveals the bottom worth (ca. 2.2 Ω cm2) amongst these reported for current intercalation electrodes (5.2 to 235 Ω cm2). Compared of the unfavourable electrodes, the estimated most present density with out Li deposition (ca. 316 mA cm-2) is greater than 1 order of magnitude larger than that for at present used graphite (ca. 11 mA cm-2) and can also be larger than these for high-rate oxides (137-298 mA cm-2).
The resistance-crystal correlation utilizing a number of regression evaluation predictions and its verification reveal that this low resistance is owing to an improved Li acceptability related to selective structural defects induced by the lack of included crystallized water throughout drying. The crystal aircraft uncovered by the selective structural defects is perpendicular to digital and ionic conduction instructions contained in the stable, leading to improved kinetics. Subsequently, the proposed unfavourable electrode permits secure and quick charging, with straightforward scale-up and sustainable sources.
Purposeful Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance
Drug resistance is a generally unavoidable consequence of most cancers remedy that ends in remedy failure and illness relapse. Intrinsic (pre-existing) or acquired resistance mechanisms could be drug-specific or be relevant to a number of medicine, leading to multidrug resistance. The presence of drug resistance is, nonetheless, tightly coupled to modifications in mobile homeostasis, which might result in resistance-coupled vulnerabilities. Unbiased gene perturbations by way of RNAi and CRISPR applied sciences are invaluable instruments to determine genotype-to-phenotype relationships on the genome scale.
Furthermore, their software to most cancers cell strains can uncover new vulnerabilities which are related to resistance mechanisms. Right here, we focus on focused and unbiased RNAi and CRISPR efforts within the discovery of drug resistance mechanisms by specializing in first-in-line chemotherapy and their enforced vulnerabilities, and we current a view ahead on which measures ought to be taken to speed up their medical translation.
Induction of ADAM10 by RT drives fibrosis, resistance, and EMT in pancreatic most cancers
Stromal fibrosis prompts pro-survival and pro-epithelial-to-mesenchymal transition (EMT) pathways in pancreatic ductal adenocarcinoma (PDAC). In affected person tumors handled with neoadjuvant stereotactic physique radiation remedy (SBRT), we discovered upregulation of fibrosis, extracellular matrix (ECM), and EMT gene signatures, which might drive therapeutic resistance and tumor invasion. Molecular, practical, and translational evaluation recognized two cell floor proteins, A disintegrin and metalloprotease 10 (ADAM10) and ephrinB2, as drivers of fibrosis and tumor development after RT. RT resulted in elevated ADAM10 expression in tumor cells, resulting in cleavage of ephrinB2, which was additionally detected in plasma.
Pharmacologic or genetic focusing on of ADAM10 decreased RT-induced fibrosis and tissue rigidity, tumor cell migration, and invasion, sensitizing orthotopic tumors to radiation killing and prolonging mouse survival. Inhibition of ADAM10 and genetic ablation of ephrinB2 in fibroblasts decreased the metastatic potential of tumor cells after RT. Stimulation of tumor cells with EphrinB2 FC-protein reversed the discount in tumor cell invasion with ADAM10 ablation. These findings signify a mannequin of PDAC adaptation that explains resistance and metastasis after radiation remedy and identifies a targetable pathway to reinforce RT efficacy.
Exogenous and endogenous sources of serine contribute to colon most cancers metabolism, development, and resistance to 5-fluorouracil
Serine is a non-essential amino acid generated by the sequential actions of phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase (PSAT1), and phosphoserine phosphatase (PSPH). Elevated serine biosynthesis happens in a number of cancers and helps tumor development. Moreover, most cancers cells can harness exogenous serine to reinforce their metabolism and proliferation. Right here we examined the relative contributions of exogenous and endogenous sources of serine on the biology of colorectal most cancers (CRC). In murine tumors, Apc standing was recognized as a determinant of the expression of genes controlling serine synthesis.
In affected person samples, PSAT1 was overexpressed in each colorectal adenomas and adenocarcinomas. Combining genetic deletion of PSAT1 with exogenous serine deprivation maximally suppressed the proliferation of CRC cells and induced profound metabolic defects together with diminished nucleotide manufacturing. Inhibition of serine synthesis enhanced the transcriptional modifications following exogenous serine elimination in addition to alterations related to DNA injury.
 ELISA Kit) Human Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) ELISA Kit |
|
RD-BCAR1-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 521 |
Human Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) ELISA Kit |
|
RD-BCAR1-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 723 |
 BCAR1 antibody |
|
70R-15968 |
Fitzgerald |
50 ul |
EUR 435 |
|
Description: Rabbit polyclonal BCAR1 antibody |
 BCAR1 Antibody |
|
37147-100ul |
SAB |
100ul |
EUR 252 |
BCAR1 antibody |
|
10R-3418 |
Fitzgerald |
100 ul |
EUR 691 |
|
Description: Mouse monoclonal BCAR1 antibody |
BCAR1 antibody |
|
10R-3420 |
Fitzgerald |
100 ul |
EUR 691 |
|
Description: Mouse monoclonal BCAR1 antibody |
BCAR1 antibody |
|
10R-3421 |
Fitzgerald |
100 ul |
EUR 726 |
|
Description: Mouse monoclonal BCAR1 antibody |
BCAR1 Antibody |
|
1-CSB-PA002593GA01HU |
Cusabio |
|
|
- Form: Liquid
- Buffer: PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20℃, Avoid freeze / thaw cycles. Antigen Affinity purified
|
|
Description: A polyclonal antibody against BCAR1. Recognizes BCAR1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF |
BCAR1 Antibody |
|
1-CSB-PA002593LA01HU |
Cusabio |
|
|
- Form: Liquid
- Buffer: Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
|
|
Description: A polyclonal antibody against BCAR1. Recognizes BCAR1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF; Recommended dilution: WB:1:500-1:5000, IHC:1:20-1:200, IF:1:50-1:200 |
BCAR1 Antibody |
|
1-CSB-PA003613 |
Cusabio |
|
|
- Form: Liquid
- Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
|
|
Description: A polyclonal antibody against BCAR1. Recognizes BCAR1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/10000 |
BCAR1 Antibody |
|
1-CSB-PA003614 |
Cusabio |
|
|
- Form: Liquid
- Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
|
|
Description: A polyclonal antibody against BCAR1. Recognizes BCAR1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/5000 |
BCAR1 Antibody |
|
1-CSB-PA134376 |
Cusabio |
|
|
- Form: Liquid
- Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
|
|
Description: A polyclonal antibody against BCAR1. Recognizes BCAR1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
BCAR1 Antibody |
|
1-CSB-PA941444 |
Cusabio |
|
|
- Form: Liquid
- Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
|
|
Description: A polyclonal antibody against BCAR1. Recognizes BCAR1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100 |
 BCAR1 siRNA |
|
20-abx900603 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
BCAR1 siRNA |
|
20-abx908938 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
BCAR1 siRNA |
|
20-abx908939 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
 anti-BCAR1 |
|
YF-PA16392 |
Abfrontier |
50 ul |
EUR 363 |
|
Description: Mouse polyclonal to BCAR1 |
anti-BCAR1 |
|
YF-PA16393 |
Abfrontier |
50 ug |
EUR 363 |
|
Description: Mouse polyclonal to BCAR1 |
anti-BCAR1 |
|
YF-PA16394 |
Abfrontier |
100 ug |
EUR 403 |
|
Description: Rabbit polyclonal to BCAR1 |
 (CMV) (pLenti-GIII-CMV)) BCAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV672493 |
ABM |
1.0 ug DNA |
EUR 1355 |
 (UbC) (pLenti-GIII-UbC)) BCAR1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV672497 |
ABM |
1.0 ug DNA |
EUR 1355 |
 (EF1a) (pLenti-GIII-EF1a)) BCAR1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV672498 |
ABM |
1.0 ug DNA |
EUR 1355 |
 (pORF)) Bcar1 ORF Vector (Rat) (pORF) |
|
ORF063985 |
ABM |
1.0 ug DNA |
EUR 506 |
 (pORF)) BCAR1 ORF Vector (Human) (pORF) |
|
ORF016109 |
ABM |
1.0 ug DNA |
EUR 405 |
 (pORF)) Bcar1 ORF Vector (Mouse) (pORF) |
|
ORF039734 |
ABM |
1.0 ug DNA |
EUR 506 |
Bcar1 ORF Vector (Mouse) (pORF) |
|
ORF039735 |
ABM |
1.0 ug DNA |
EUR 506 |
 BCAR1 Rabbit pAb |
|
A0855-100ul |
Abclonal |
100 ul |
EUR 308 |
BCAR1 Rabbit pAb |
|
A0855-200ul |
Abclonal |
200 ul |
EUR 459 |
BCAR1 Rabbit pAb |
|
A0855-20ul |
Abclonal |
20 ul |
Ask for price |
BCAR1 Rabbit pAb |
|
A0855-50ul |
Abclonal |
50 ul |
EUR 223 |
 BCAR1 Conjugated Antibody |
|
C37147 |
SAB |
100ul |
EUR 397 |
 Antibody) BCAR1 (pY410) Antibody |
|
abx333314-100ul |
Abbexa |
100 ul |
EUR 467 |
- Shipped within 5-10 working days.
|
BCAR1 Rabbit pAb |
|
A18270-100ul |
Abclonal |
100 ul |
EUR 308 |
BCAR1 Rabbit pAb |
|
A18270-200ul |
Abclonal |
200 ul |
EUR 459 |
BCAR1 Rabbit pAb |
|
A18270-20ul |
Abclonal |
20 ul |
EUR 183 |
BCAR1 Rabbit pAb |
|
A18270-50ul |
Abclonal |
50 ul |
EUR 223 |
 Anti-BCAR1 antibody |
|
STJ11100226 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: The protein encoded by this gene is a member of the Crk-associated substrate (CAS) family of scaffold proteins, characterized by the presence of multiple protein-protein interaction domains and many serine and tyrosine phosphorylation sites. The encoded protein contains a Src-homology 3 (SH3) domain, a proline-rich domain, a substrate domain which contains 15 repeat of the YxxP consensus phosphorylation motif for Src family kinases, a serine-rich domain, and a bipartite Src-binding domain, which can bind both SH2 and SH3 domains. This adaptor protein functions in multiple cellular pathways, including in cell motility, apoptosis and cell cycle control. Dysregulation of this gene can have a wide range of effects, affecting different pathways, including cardiac development, vascular smooth muscle cells, liver and kidney function, endothelial migration, and cancer. |
 BCAR1 Antibody, HRP conjugated |
|
1-CSB-PA002593LB01HU |
Cusabio |
|
|
- Form: Liquid
- Buffer: Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
|
|
Description: A polyclonal antibody against BCAR1. Recognizes BCAR1 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
 BCAR1 Antibody, FITC conjugated |
|
1-CSB-PA002593LC01HU |
Cusabio |
|
|
- Form: Liquid
- Buffer: Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
|
|
Description: A polyclonal antibody against BCAR1. Recognizes BCAR1 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
 BCAR1 Antibody, Biotin conjugated |
|
1-CSB-PA002593LD01HU |
Cusabio |
|
|
- Form: Liquid
- Buffer: Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
|
|
Description: A polyclonal antibody against BCAR1. Recognizes BCAR1 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
 Antibody) Phospho-BCAR1 (Y410) Antibody |
|
1-CSB-PA080024 |
Cusabio |
|
|
- Form: Liquid
- Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
|
|
Description: A polyclonal antibody against Phospho-BCAR1 (Y410). Recognizes Phospho-BCAR1 (Y410) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/5000 |
 Antibody) Phospho-BCAR1 (Y165) Antibody |
|
1-CSB-PA080025 |
Cusabio |
|
|
- Form: Liquid
- Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
|
|
Description: A polyclonal antibody against Phospho-BCAR1 (Y165). Recognizes Phospho-BCAR1 (Y165) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/5000 |
 Antibody) Phospho-BCAR1 (Y249) Antibody |
|
1-CSB-PA080026 |
Cusabio |
|
|
- Form: Liquid
- Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
|
|
Description: A polyclonal antibody against Phospho-BCAR1 (Y249). Recognizes Phospho-BCAR1 (Y249) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/10000 |
 Antibody) BCAR1 (Ab-410) Antibody |
|
CSB-PA094765- |
Cusabio |
|
EUR 335 |
- Form: liquid
- Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
- Show more
|
|
Description: A polyclonal antibody against BCAR1 (Ab-410). Recognizes BCAR1 (Ab-410) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:3000, IHC:1:50-1:100 |
BCAR1 (Ab-410) Antibody |
|
CSB-PA094765-100ul |
Cusabio |
100ul |
EUR 316 |
- Form: liquid
- Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
- Show more
|
|
Description: A polyclonal antibody against BCAR1 (Ab-410). Recognizes BCAR1 (Ab-410) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:3000, IHC:1:50-1:100 |
 Antibody) Phospho-BCAR1 (Tyr410) Antibody |
|
CSB-PA975216- |
Cusabio |
|
EUR 335 |
- Form: liquid
- Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodie
- Show more
|
|
Description: A polyclonal antibody against Phospho-BCAR1 (Tyr410). Recognizes Phospho-BCAR1 (Tyr410) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:1000, IHC:1:50-1:100 |
Phospho-BCAR1 (Tyr410) Antibody |
|
CSB-PA975216-100ul |
Cusabio |
100ul |
EUR 362 |
- Form: liquid
- Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodie
- Show more
|
|
Description: A polyclonal antibody against Phospho-BCAR1 (Tyr410). Recognizes Phospho-BCAR1 (Tyr410) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:1000, IHC:1:50-1:100 |
) BCAR1 protein (His tag) |
|
80R-3671 |
Fitzgerald |
50 ug |
EUR 435 |
|
Description: Purified recombinant BCAR1 protein (His tag) |
 Rat BCAR1 shRNA Plasmid |
|
20-abx985003 |
Abbexa |
|
|
- Shipped within 15-20 working days.
|
 BCAR1 Cell ELISA Kit |
|
abx595057-96tests |
Abbexa |
96 tests |
EUR 637 |
- Shipped within 1-2 weeks.
|
 Human BCAR1 shRNA Plasmid |
|
20-abx956363 |
Abbexa |
|
|
- Shipped within 15-20 working days.
|
 Mouse BCAR1 shRNA Plasmid |
|
20-abx969811 |
Abbexa |
|
|
- Shipped within 15-20 working days.
|
 (CMV) (pLenti-GIII-CMV-C-term-HA)) BCAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV672494 |
ABM |
1.0 ug DNA |
EUR 1355 |
 (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)) BCAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV672495 |
ABM |
1.0 ug DNA |
EUR 1413 |
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)) BCAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV672496 |
ABM |
1.0 ug DNA |
EUR 1413 |
 (pPB-C-His)) BCAR1 Protein Vector (Mouse) (pPB-C-His) |
|
PV158934 |
ABM |
500 ng |
EUR 1065 |
 (pPB-N-His)) BCAR1 Protein Vector (Mouse) (pPB-N-His) |
|
PV158935 |
ABM |
500 ng |
EUR 1065 |
 (pPM-C-HA)) BCAR1 Protein Vector (Mouse) (pPM-C-HA) |
|
PV158936 |
ABM |
500 ng |
EUR 1065 |
 (pPM-C-His)) BCAR1 Protein Vector (Mouse) (pPM-C-His) |
|
PV158937 |
ABM |
500 ng |
EUR 1065 |
BCAR1 Protein Vector (Mouse) (pPB-C-His) |
|
PV158938 |
ABM |
500 ng |
EUR 1065 |
BCAR1 Protein Vector (Mouse) (pPB-N-His) |
|
PV158939 |
ABM |
500 ng |
EUR 1065 |
BCAR1 Protein Vector (Mouse) (pPM-C-HA) |
|
PV158940 |
ABM |
500 ng |
EUR 1065 |
BCAR1 Protein Vector (Mouse) (pPM-C-His) |
|
PV158941 |
ABM |
500 ng |
EUR 1065 |
 (pPB-C-His)) BCAR1 Protein Vector (Rat) (pPB-C-His) |
|
PV255938 |
ABM |
500 ng |
EUR 1166 |
 (pPB-N-His)) BCAR1 Protein Vector (Rat) (pPB-N-His) |
|
PV255939 |
ABM |
500 ng |
EUR 1166 |
 (pPM-C-HA)) BCAR1 Protein Vector (Rat) (pPM-C-HA) |
|
PV255940 |
ABM |
500 ng |
EUR 1166 |
 (pPM-C-His)) BCAR1 Protein Vector (Rat) (pPM-C-His) |
|
PV255941 |
ABM |
500 ng |
EUR 1166 |
 (pPB-His-MBP)) BCAR1 Protein Vector (Human) (pPB-His-MBP) |
|
PV326406 |
ABM |
500 ng |
EUR 811 |
 (pPB-His-GST)) BCAR1 Protein Vector (Human) (pPB-His-GST) |
|
PV326407 |
ABM |
500 ng |
EUR 811 |
 (pPB-C-His)) BCAR1 Protein Vector (Human) (pPB-C-His) |
|
PV064433 |
ABM |
500 ng |
EUR 811 |
 (pPB-N-His)) BCAR1 Protein Vector (Human) (pPB-N-His) |
|
PV064434 |
ABM |
500 ng |
EUR 811 |
 (pPM-C-HA)) BCAR1 Protein Vector (Human) (pPM-C-HA) |
|
PV064435 |
ABM |
500 ng |
EUR 811 |
 (pPM-C-His)) BCAR1 Protein Vector (Human) (pPM-C-His) |
|
PV064436 |
ABM |
500 ng |
EUR 811 |
) Polyclonal MOUSE Bcar1 Antibody (Center) |
|
APR04569G |
Leading Biology |
0.1ml |
EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human MOUSE Bcar1 (Center). This antibody is tested and proven to work in the following applications: |
 Phospho-BCAR1-Y410 Rabbit pAb |
|
AP0789-100ul |
Abclonal |
100 ul |
EUR 384 |
Phospho-BCAR1-Y410 Rabbit pAb |
|
AP0789-200ul |
Abclonal |
200 ul |
EUR 554 |
Phospho-BCAR1-Y410 Rabbit pAb |
|
AP0789-20ul |
Abclonal |
20 ul |
EUR 183 |
Phospho-BCAR1-Y410 Rabbit pAb |
|
AP0789-50ul |
Abclonal |
50 ul |
EUR 265 |
 Phospho-BCAR1-Y165 Rabbit pAb |
|
AP0813-100ul |
Abclonal |
100 ul |
EUR 384 |
Phospho-BCAR1-Y165 Rabbit pAb |
|
AP0813-200ul |
Abclonal |
200 ul |
EUR 554 |
Phospho-BCAR1-Y165 Rabbit pAb |
|
AP0813-20ul |
Abclonal |
20 ul |
EUR 183 |
Phospho-BCAR1-Y165 Rabbit pAb |
|
AP0813-50ul |
Abclonal |
50 ul |
EUR 265 |
Phospho-BCAR1-Y410 Rabbit pAb |
|
AP1058-100ul |
Abclonal |
100 ul |
EUR 384 |
Phospho-BCAR1-Y410 Rabbit pAb |
|
AP1058-200ul |
Abclonal |
200 ul |
EUR 554 |
Phospho-BCAR1-Y410 Rabbit pAb |
|
AP1058-20ul |
Abclonal |
20 ul |
EUR 183 |
Phospho-BCAR1-Y410 Rabbit pAb |
|
AP1058-50ul |
Abclonal |
50 ul |
EUR 265 |
) Polyclonal BCAR1 Antibody (internal region) |
|
APG00909G |
Leading Biology |
0.1mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human BCAR1 (internal region). This antibody is tested and proven to work in the following applications: |
 Cell ELISA Kit) BCAR1 (pY410) Cell ELISA Kit |
|
abx595988-296tests |
Abbexa |
2 × 96 tests |
EUR 707 |
- Shipped within 1-2 weeks.
|
 Anti-Phospho-BCAR1-Y410 antibody |
|
STJ11101096 |
St John's Laboratory |
100 µl |
EUR 393 |
|
Description: The protein encoded by this gene is a member of the Crk-associated substrate (CAS) family of scaffold proteins, characterized by the presence of multiple protein-protein interaction domains and many serine and tyrosine phosphorylation sites. The encoded protein contains a Src-homology 3 (SH3) domain, a proline-rich domain, a substrate domain which contains 15 repeat of the YxxP consensus phosphorylation motif for Src family kinases, a serine-rich domain, and a bipartite Src-binding domain, which can bind both SH2 and SH3 domains. This adaptor protein functions in multiple cellular pathways, including in cell motility, apoptosis and cell cycle control. Dysregulation of this gene can have a wide range of effects, affecting different pathways, including cardiac development, vascular smooth muscle cells, liver and kidney function, endothelial migration, and cancer. |
 (OKCD01928)) BCAR1 ELISA Kit (Human) (OKCD01928) |
|
OKCD01928 |
Aviva Systems Biology |
96 Wells |
EUR 831 |
|
Description: Description of target: Docking protein which plays a central coordinating role for tyrosine kinase-based signaling related to cell adhesion. Implicated in induction of cell migration. Overexpression confers antiestrogen resistance on breast cancer cells.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich Immunoassay;Sensitivity: < 27 pg/mL |
 BCAR1 Colorimetric Cell-Based ELISA Kit |
|
EKC1054 |
BosterBio |
100ul |
EUR 572 |
) Bcar1 sgRNA CRISPR Lentivector set (Rat) |
|
K6802201 |
ABM |
3 x 1.0 ug |
EUR 339 |
) BCAR1 sgRNA CRISPR Lentivector set (Human) |
|
K0173301 |
ABM |
3 x 1.0 ug |
EUR 339 |
) Bcar1 sgRNA CRISPR Lentivector set (Mouse) |
|
K3814401 |
ABM |
3 x 1.0 ug |
EUR 339 |
 (pPM-N-D-C-HA)) BCAR1 Protein Vector (Human) (pPM-N-D-C-HA) |
|
PV326408 |
ABM |
500 ng |
Ask for price |
 (pPM-N-D-C-His)) BCAR1 Protein Vector (Human) (pPM-N-D-C-His) |
|
PV326409 |
ABM |
500 ng |
Ask for price |
 (Target 1)) Bcar1 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|
K6802202 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) Bcar1 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|
K6802203 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 3)) Bcar1 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|
K6802204 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 1)) BCAR1 sgRNA CRISPR Lentivector (Human) (Target 1) |
|
K0173302 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) BCAR1 sgRNA CRISPR Lentivector (Human) (Target 2) |
|
K0173303 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 3)) BCAR1 sgRNA CRISPR Lentivector (Human) (Target 3) |
|
K0173304 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 1)) Bcar1 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|
K3814402 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) Bcar1 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|
K3814403 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 3)) Bcar1 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|
K3814404 |
ABM |
1.0 ug DNA |
EUR 154 |
 Recombinant Human BCAR1 Protein, His, E.coli-10ug |
|
QP11133-10ug |
EnQuireBio |
10ug |
EUR 201 |
 Recombinant Human BCAR1 Protein, His, E.coli-1mg |
|
QP11133-1mg |
EnQuireBio |
1mg |
EUR 5251 |
 Recombinant Human BCAR1 Protein, His, E.coli-2ug |
|
QP11133-2ug |
EnQuireBio |
2ug |
EUR 155 |
 Bcar1 3'UTR GFP Stable Cell Line |
|
TU152663 |
ABM |
1.0 ml |
Ask for price |
 Bcar1 3'UTR Luciferase Stable Cell Line |
|
TU102663 |
ABM |
1.0 ml |
Ask for price |
Bcar1 3'UTR Luciferase Stable Cell Line |
|
TU201255 |
ABM |
1.0 ml |
Ask for price |
Bcar1 3'UTR GFP Stable Cell Line |
|
TU251255 |
ABM |
1.0 ml |
Ask for price |
 BCAR1 3'UTR GFP Stable Cell Line |
|
TU051676 |
ABM |
1.0 ml |
EUR 1394 |
 BCAR1 3'UTR Luciferase Stable Cell Line |
|
TU001676 |
ABM |
1.0 ml |
EUR 1394 |
) BCAR1 Colorimetric Cell-Based ELISA Kit (OKAG00547) |
|
OKAG00547 |
Aviva Systems Biology |
96 Wells |
EUR 596 |
|
Description: Description of target: ;Species reactivity: Human, Mouse, Rat;Application: ELISA;Assay info: Assay Type: Cell-Based
Subtype: None
Detection Method: Colorimetric 450 nm;Sensitivity: |
 Antibody) Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) Antibody |
|
20-abx213819 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) Antibody |
|
20-abx214090 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) Antibody |
|
20-abx111258 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
Each lack of PSAT1 and elimination of serine from the weight loss plan had been essential to suppress CRC xenograft development and improve the anti-tumor exercise of 5-fluorouracil (5-FU). Limiting endogenous and exogenous serine in vitro augmented 5-FU induced cell dying, DNA injury, and metabolic perturbations, probably accounting for the noticed anti-tumor impact. Collectively, our outcomes counsel that each endogenous and exogenous sources of serine contribute to CRC development and resistance to 5-FU.
 antibody)
 antibody)